Treatment of Antibody-Mediated Rejection (ABMR) With CarBel
Public ClinicalTrials.gov record NCT06918990. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Targeting the B Cell Response to Treat Antibody-Mediated Rejection With Carfilzomib and Belatacept (CarBel)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to evaluate the safety of carfilzomib and belatacept, administered with steroids and maintenance immunosuppression, in kidney transplant recipients with donor-specific antibody (DSA)-associated graft injury. Participants will be followed for 52 weeks after starting investigational therapy, including protocol biopsies at 3 months and 12 months after start of investigational therapy. The study will also assess changes in immune cell responses, blood and urine biomarkers, and biopsy-based pathomic features associated with antibody-mediated graft injury.
Study identification
- NCT ID
- NCT06918990
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 25 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 26, 2026
- Primary completion
- Jun 29, 2027
- Completion
- Jun 29, 2027
- Last update posted
- Aug 9, 2026
2026 – 2027
United States locations
- U.S. sites
- 11
- U.S. states
- 9
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama Medical Center (Site # 71136) | Birmingham | Alabama | 35294 | Not yet recruiting |
| Mayo Clinic Arizona (Site # 71144) | Phoenix | Arizona | 85054 | Recruiting |
| UCLA Medical Center (Site #: 71123) | Los Angeles | California | 90024 | Not yet recruiting |
| Northwestern University, Feinberg School of Medicine (Site # 71110) | Chicago | Illinois | 60611 | Recruiting |
| Washington University (Site # 71157) | St Louis | Missouri | 63110 | Recruiting |
| NYU Langone Health (Site # 71177) | New York | New York | 10016 | Recruiting |
| Duke University (Site # 71139) | Durham | North Carolina | 27710 | Recruiting |
| Christ Hospital (Site # 71195) | Cincinnati | Ohio | 45267 | Not yet recruiting |
| University of Cincinnati (Site # 71118) | Cincinnati | Ohio | 45267 | Recruiting |
| Cleveland Clinic (Site # 71101) | Cleveland | Ohio | 44195 | Recruiting |
| University of Wisconsin Madison (Site # 71112) | Madison | Wisconsin | 53726 | Not yet recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06918990, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 9, 2026 · Synced Sep 11, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06918990 live on ClinicalTrials.gov.